What type of study is this?

This is a Quantitative Study study.

September 27, 2025Cancer Research

Abstract A023-PR006: CBL mutations in pediatric solid and CNS tumours are a marker of receptor tyrosine kinase activation and a potential therapeutic target

View Full Paper

Ask AI

Bookmark

Authors

Molecular analysis identifies CBL mutations in pediatric tumors, suggesting potential for targeted therapies.

CBL mutations appear in pediatric CNS and solid tumors, indicating receptor tyrosine kinase activation.
Among mutations, 72% clustered in key functional domains, highlighting their potential pathogenic role.
Whole genome analysis revealed 34 somatic and 2 germline CBL variants in a cohort of patients.
Findings suggest that CBL mutations can extend the therapeutic benefits of tyrosine kinase inhibitors.

Brown et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark